Investigation of MDR1 Gene Polymorphism and Losartan Plasma Concentration in Patients Undergoing Hypertensive Episodes While Under Losartan Treatment

Completed

• Conditions: Hypertension
• Interventions: Diagnostic Test: Genetic analysis and Losartan plazma level measurement

• Registration Number: NCT05349825
• Lead Sponsor: Pamukkale University

Brief Summary

Losartan is an antihypertensive drug belonging to the ARB family. It is characterized as the substrate of the Multi Drug Resistance-1 (MDR1) drug-efflux protein (a pump that ensures the removal of drugs/foreign substances out of the cell) encoded by the ATP Binding Cassette Subfamily B Member 1 (ABCB1) gene. A recent line of evidence indicates that potential polymorphisms in this gene tend to alter the absorption, transport, bioavailability of losartan, and, indirectly, its effectiveness in hypertension control. As identified by new research, the C3435T, G2677T, and C1236T polymorphic alleles of the MDR1 gene might alter the bioavailability and thus the effectiveness of losartan

Detailed Description

This trial was conducted in the emergency services of Gazi University and Pamukkale University. The patient group was comprised of 50 individuals presenting with a hypertensive episode (patients under 60, \>140/90 mmHg, patients over 60, \>150/90 mmHg, according to the JNC8 guidelines) while under losartan treatment. The control group, by contrast, included 50 patients whose blood pressure was regulated while receiving losartan treatment and who were admitted to the ED for reasons other than hypertensive episode. The eligible patients matching the inclusion and exclusion criteria were recruited for the study.

Within the scope of this research, we included hypertension patients over 18 who gave their informed consent for the study and received minimum 25 mg losartan daily for at least six weeks. 50 individuals admitted to the ED due to a hypertensive episode while under losartan treatment were assigned to the patient group, while 50 patients whose blood pressure was regulated while receiving losartan treatment and who were admitted to the ED for reasons other than hypertensive episode were included in the control group. Those who did not give their consent to participate and did not match the inclusion criteria were excluded from the scope of the study Prior to the trial, the participants were assessed based on the pre-defined patient selection criteria, and the non-eligible ones were excluded from the trial. These exclusion criteria can be listed as refusal to participate in the study, illiteracy, being under 18, being pregnant and in lactation period, being hemodynamically unstable (mean arterial pressure \<65mmHg), undergoing kidney transplantation, having liver failure (CHILD PUGH Class C and higher patients) or renal failure (GFR\<60), and taking anti-hypertensive drugs other than losartan(Figure 1).

Initially, 20 ml of blood was collected from the enrolled patients. 10 ml of blood was stored in the tubes with ethylene diamine tetraacetic acid (EDTA) until Deoxyribonucleic acid (DNA) isolation was performed at -20 degrees and plasma level was identified. The remaining 10 ml was centrifuged at 3500 rpm for 10 min, and the plasma was separated. The resulting plasmas were stored in the eppendorf tubes at -20°C until the tandem mass spectrometry measurement.

Study Timeline

• Study Start: 2017-10-23
• Primary Completion: 2019-01-15
• Study Completion: 2019-01-15
• Status Verified: 2022-04
• Study First Submitted: 2022-04-18
• Study First Submitted QC: 2022-04-22
• Last Update Submitted: 2022-04-22
• Study First Posted: 2022-04-27
• Last Update Posted: 2022-04-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• gave their informed consent
• received minimum 25 mg losartan daily for at least six weeks

Exclusion Criteria

• refusal to participate in the study
• illiteracy
• pregnant or in lactation period
• hemodynamically unstable (mean arterial pressure <65mmHg)
• kidney transplantation
• liver failure (CHILD PUGH Class C and higher patients) or renal failure (GFR<60)
• taking anti-hypertensive drugs other than losartan

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Patients with Hypertensive episode	Genetic analysis and Losartan plazma level measurement	50 individuals presenting with a hypertensive episode (patients under 60, \>140/90 mmHg, patients over 60, \>150/90 mmHg, according to the JNC8 guidelines) while under losartan treatment
Patients with controlled hypertension	Genetic analysis and Losartan plazma level measurement	50 patients whose blood pressure was regulated while receiving losartan treatment and who were admitted to the ED for reasons other than hypertensive episode. The eligible patients matching the inclusion and exclusion criteria were recruited for the study.

Primary Outcome Measures

Name	Time	Method
MDR1 gene polimorphism does not influence losartan consantration nevertheless changes blood pressure lowering effect of losartan	at least six weeks under losartan treatment	50 patients receiving anti-hypertensive treatment with losartan, presenting to the ED with a hypertensive episode and 50 patients whose blood pressure was regulated while receiving losartan treatment and who presented to the ED for reasons other than hypertensive episode. Compare two groups losartan consantration and MDR1 gene polymorphyms

Trial Locations

Locations (1)

Gazi University; 🇹🇷 Ankara, Turkey